Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903888 | 1.00 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL1845669 | 1.00 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL15159951 | 0.93 | ATM (0.73) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL2617278 | 0.89 | ATM (0.57) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL29060748 | 0.89 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL13999532 | 0.89 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL30487217 | 0.89 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL13999332 | 0.89 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL28678626 | 0.89 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL257912 | 0.89 | ATM (0.71) | ATMAPPCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| CN-107001259-A | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2231628-B1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2009088719-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | ATM 4182/4885APP 4191/4885CTSS 1167/4885 |
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | ATM 2199/4885APP 1270/4885CTSS 2941/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | ATM 2199/4885APP 1270/4885CTSS 2941/4885 |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | ATM 45/4885APP 3143/4885CTSS 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.